CT引导下放射性125I粒子植入治疗难治性肝转移癌的临床观察

目的 评价CT引导下放射性¹²⁵I粒子植入近距离放射治疗难治性肝转移癌的临床价值。方法 2010年1月至2012年1月在CT引导下实施¹²⁵I粒子植入治疗的40例难治性肝转移癌患者，共有可测量病灶94个。评价临床疗效、术后并发症及不良反应。结果 至植入术后6个月时，94个病灶中获完全缓解（CR）32个，部分缓解 （PR） 48个，稳定 （SD） 9个，进展 （PD） 5个，有效率 （RR）为85.1％。术后随访时间为4～31个月，平均13个月。至随访结束时，1年生存率为75.0％。无手术相关的严重并发症及3～4级不良反应。结论 CT引导下¹²⁵I粒子植入治疗的疗效确切、毒副反应少，可作为难治性肝转移癌新的有效治疗手段。

Clinical observation of CT-guided125I seed implantation on refractory metastatic liver cancer

Objective To evaluate the clinical value of CT-guided radioactive 1251 seed implantation brachytherapy for refrac- tory metastatic liver cancer. Methods Forty refractory metastatic liver cancer patients with 94 measurable metastatic loci were treated under the CT-guided with the 125I radioactivity seed interstitial brachytherapy from January 2010 to January 2012. The clinical effects, postoperative complications and adverse reactions were evaluated. Results After operation for 6 months, of all the 94 measurable me- tastatic loci, 32 loci got complete response （CR） , partial response （CR） was observed in 48 foci, stable disease（SD） in 9 loci and progressive disease （PD） in 5 loci. The response rate （RR） was 85.1%. The follow-up ranged from 4 to 31 months （average 13 months）. At the end of the follow-up period, 1-year survival rate was 75.0%. No serious operative or postoperative complications and grade 3-4 adverse effects occurred. Conclusion CT-guided 125I seed implantation brachytherapy showed good clinical effects but fewer side effects. It can be used as a new treatment option for patients with refractory metastatic liver cancer.